A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease

Neurology

Volumn 67, Issue 7 SUPPL. 2, 2006, Pages

  Zecca, L ^a,d   Zucca, F A ^a   Albertini, A ^a   Rizzio, E ^b   Fariello, R G ^c  

^a INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^b Unit of Radiochemistry and Spectroscopy   (Italy)

^c Newron Pharmaceuticals R and D Department   (Italy)

^d CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL AGENT; INTERLEUKIN 6; NEUROMELANIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL GRANULE; CELL ORGANELLE; CYTOKINE RELEASE; DISEASE COURSE; DISEASE EXACERBATION; HUMAN; IRON CHELATION; MICROGLIA; PARKINSON DISEASE; PARKINSONISM; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; SUBSTANTIA NIGRA; SYMPTOMATOLOGY;

EID: 33749989574     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.7_suppl_2.s8     Document Type: Article

References (46)

1. Ehringer H, Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 1960;38:1236-1239. In German.
2. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961;73:787-788. In German.
3. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983;219:979-980.
4. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
5. Fahn S, Sulzer D. Neurodegeneration and neuroprotection in Parkinson disease. NeuroRx 2004;1:139-154.
6. Zecca L, Stroppolo A, Gatti A, et al. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 2004;101:9843-9848.
7. Sulzer D, Bogulavsky J, Larsen KE, et al. Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc Natl Acad Sci USA 2000;97:11869-11874.
8. Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC. Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons. J Comp Neurol 2004;473:97-106.
9. Zecca L, Costi P, Mecacci C, Ito S, Terreni M, Sonnino S. Interaction of human substantia nigra neuromelanin with lipids and peptides. J Neurochem 2000;74:1758-1765.
10. Double KL, Zecca L, Costi P, et al. Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J Neurochem 2000;75:2583-2589.
11. Wakamatsu K, Fujikawa K, Zucca FA, Zecca L, Ito S. The structure of neuromelanin as studied by chemical degradative methods. J Neurochem 2003;86:1015-1023.
12. Crippa R, Wang QJ, Eisner M, et al. Structure of human neuromelanin by X-ray diffraction: comparison with synthetics. Proc XVI Internat Pigment Cell Conference 1996. Abstract.
13. Cheng J, Moss SC, Eisner M. X-ray characterization of melanins-II. Pigment Cell Res 1994;7:263-273.
14. Zecca L, Zucca FA, Wilms H, Sulzer D. Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends Neurosci 2003;26:578-580.
15. Barden H. The histochemical relationship of neuromelanin and lipofuscin. J Neuropathol Exp Neurol 1969;28:419-441.
16. Mann DM, Yates PO. Lipoprotein pigments - their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 1974;97:489-498.
17. Braak H, Braak E. Nuclear configuration and neuronal types of the nucleus niger in the brain of the human adult. Hum Neurobiol 1986;5:71-82.
18. Zecca L, Pietra R, Goj C, Mecacci C, Radice D, Sabbioni E. Iron and other metals in neuromelanin, substantia nigra, and putamen of human brain. J Neurochem 1994;62:1097-1101.
19. Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem 1992;59:1168-1171.
20. Perl DP, Good PF. Comparative techniques for determining cellular iron distribution in brain tissues. Ann Neurol 1992;32 (suppl) S76-81.
21. Shima T, Sarna T, Swartz HM, Stroppolo A, Gerbasi R, Zecca L. Binding of iron to neuromelanin of human substantia nigra and synthetic melanin: an electron paramagnetic resonance spectroscopy study. Free Radic Biol Med 1997;23:110-119.
22. Zareba M, Bober A, Korytowski W, Zecca L, Sarna T. The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim Biophys Acta 1995;1271:343-348.
23. Perry TL, Godin DV, Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 1982;33:305-310.
24. Fariello RG, Ghilardi O, Peschechera A, Ramacci MT, Angelucci L. Regional distribution of ubiquinones and tocopherols in the mouse brain: lowest content of ubiquinols in the substantia nigra. Neuropharmacology 1988;27:1077-1080.
25. D'Amato RJ, Lipman ZP, Snyder SH. Selectivity of the parkinsonian neurotoxin MPTP: toxic metabolite MPP9+ binds to neuromelanin. Science 1986;231:987-989.
26. Lindquist NG, Larsson BS, Lyden-Sokolowski A. Autoradiography of [14C]paraquat or [14C]diquat in frogs and mice: accumulation in neuromelanin. Neurosci Lett 1988;93:1-6.
27. Ostergren A, Annas A, Skog K, Lindquist NG, Brittebo EB. Long-term retention of neurotoxic beta-carbolines in brain neuromelanin. J Neural Transm 2004;111:141-157.
28. Salazar M, Sokoloski TD, Patil PN. Binding of dopaminergic drugs by the neuromelanin of the substantia nigra, synthetic melanins and melanin granules. Fed Proc 1978;37:2403-2407.
29. Wilms H, Rosenstiel P, Sievers J, Deuschl G, Zecca L, Lucius R. Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. FASEB J 2003;17:500-502.
30. Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett 2002;510:216-220.
31. McGeer PL, McGeer EG, Suzuki JS. Aging and extrapyramidal function. Arch Neurol 1977;34:33-35.
32. Pakkenberg B, Moller A, Gundersen HJ, Mouritzen Dam A, Pakkenberg H. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimated with an unbiased stereological method. J Neurol Neurosurg Psychiatry 1991;54:30-33.
33. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res 1992;581:283-291.
34. Muthane U, Yasha TC, Shankar SK. Low numbers and no loss of melanized nigral neurons with increasing age in normal human brains from India. Ann Neurol 1998;43:283-287.
35. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991;114:2283-2301.
36. Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? J Neurochem 1992;59:1080-1089.
37. Kubis N, Faucheux BA, Ransmayr G, et al. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000;123:366-373.
38. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005;75:109-124.
39. Zucca FA, Giaveri G, Gallorini M, et al. The neuromelanin of human substantia nigra: physiological and pathogenic aspects. Pigment Cell Res 2004;17:610-617.
40. Gibb WR, Lees AJ. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:388-396.
41. Mann DM, Yates PO. Possible role of neuromelanin in the pathogenesis of Parkinson's disease. Mech Ageing Dev 1983;21:193-203.
42. Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord 2005; [Epub ahead of print]
43. Langston JW, Forno LS, Tetrud J, Reeves AG, Kaplan JA, Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Ann Neurol 1999;46:598-605.
44. Levi AC, DeMattei M, Ravazzani R, Corvetti G, Golden GT, Fariello RG. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on ultrastructure of nigral neuromelanin in Macaca fascicularis. Neurosci Lett 1989;96:271-276.
45. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nature Rev Neurosci 2004b;5:863-873.
46. Shamoto-Nagai M, Maruyama W, Akao Y, et al. Neuromelanin inhibits enzymatic activity of 26S proteasome in human dopaminergic SH-SY5Y cells. J Neural Transm 2004;111:1253-1265.